Anavex Life Sciences Corp. is filing definitive proxy materials and prioritizing engagement with the FDA and SEC regarding its regulatory path.

The entities involved

• FDA →
  • Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
  • A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
• Securities and Exchange Commission →

  government agency of the Philippines

  • BlackRock, the manager of the iShares Core MSCI EAFE ETF, has made required filings with the Securities and Exchange Commission regarding institutional holdings.Mon 16:42
  • Filing required regarding institutional holdings for Schwab Emerging Markets Equity ETF and Waterford Advisors LLC with the SEC.Mon 16:38
• Gautam Patel →

  Indian Sanskrit-language writer from Gujarat, India

  Nothing else this week.

Related events

• PAVmed is facing the requirement of regulatory clearance for its company products, while also attracting institutional investment interest.Sep 5
• Administration actions, including FDA appointments, are promoting Bitcoin and digital assets.Aug 19
• The FDA and the Securities and Exchange Commission entered into a Memorandum of Understanding (MOU) to enhance cooperation between the two agencies.Aug 31
• The FDA stated its intent to modernize regulatory processes to maintain leadership.Sep 15
• Byrna Technologies filed required documents with the Securities and Exchange Commission for annual corporate governance updates.Sun 02:50